Comparing Inogen (NASDAQ:INGN) & CardioGenics (OTCMKTS:CGNH)

CardioGenics (OTCMKTS:CGNH) and Inogen (NASDAQ:INGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Earnings & Valuation

This table compares CardioGenics and Inogen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CardioGenics	N/A	N/A	N/A	N/A	N/A
Inogen	$348.67 million	0.47	-$22.75 million	($0.86)	-7.05

CardioGenics has higher earnings, but lower revenue than Inogen.

Analyst Ratings

This is a breakdown of current recommendations for CardioGenics and Inogen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CardioGenics	0	0	0	0	0.00
Inogen	1	1	1	0	2.00

Inogen has a consensus target price of $11.00, indicating a potential upside of 81.52%. Given Inogen’s stronger consensus rating and higher probable upside, analysts clearly believe Inogen is more favorable than CardioGenics.

Insider and Institutional Ownership

89.9% of Inogen shares are owned by institutional investors. 41.4% of CardioGenics shares are owned by insiders. Comparatively, 1.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

CardioGenics has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares CardioGenics and Inogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CardioGenics	N/A	N/A	N/A
Inogen	-6.52%	-11.56%	-7.42%

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.